MHAT Hadzhi Dimitar OOD
Sliven 8800
0 studies enrolling now · 13 studies all time
What they study most
Acute Myocardial Infarction (AMI), Cardiovascular Risk, Chronic Kidney Disease, Colitis, Ulcerative, Crohn's Disease, Diabetes Mellitus, Type 2, Inflammation, Obesity, Rheumatoid Arthritis, Ulcerative Colitis
Studies at this site
- ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
- A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight — Completed
- Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes — Completed
- A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
- Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
- Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
- Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
- A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
- Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis — Completed
- A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 — Completed
- Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) — Completed
- An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed